Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

"CONFLICT OF INTEREST STATEMENT Dr. Oksana A. Shlobin has consulted for United Therapeutics, Bayer, Altavant, Aerovate, Jenssen&Jenssen and Merck, and is on the speaker bureau for UT, Bayer, and J&J. Mr. Eric Shen is an employee of United Therapeutics Corporation and owns stocks/shares in the company. Dr. Lucilla Piccari has received research funding from and served as a speaker for Janssen and Ferrer, advised Janssen, Ferrer, and United Therapeutics as well as received support for attending congresses from Janssen, MSD, and Ferrer, all of which not related to this manuscript. Dr. John A. Scandurra is an employee of Aria CV Inc. and owns stocks/shares in the company. Dr. Paul M. Hassoun serves on a scientific advisory board for Merck, an activity unrelated to the current work. Dr. Stephen J. Wort received honoraria from Janssen, MSD, Bayer, and Acceleron for advisory boards, received honoraria from Janssen for educational activity, received unrestricted research grants from Janssen and Bayer, and travel grants, conference registration and accommodation from Actelion and GSK. Dr. Sylvia M. Nikkho is an employee of Bayer AG. Dr. Steven D. Nathan a consultant for United Therapeutics, Bellerophon, Third Pole, Roche, Boehringer‐Ingelheim, Merck, and Daewoong."

"The authors would like to all the members of the Innovative Drug Development Initiative Group 3 Pulmonary Hypertension workstream for their dedication and commitment to the work of the group: Steven H. Abman, Peter Fernandes, Howard M. Lazarus, Horst Olschewski, Mitchell Psotka, Manuel J. Richter, Norman Stockbridge, Carmine Dario Vizza, Brian Allwood, Katerina Antoniou, Jonathan H. Chung and, Patrizio Vitulo. Finally, thank you to the IDDI Leads: Paul Corris, Raymond Benza, Mark Toshner and to the Pulmonary Vascular Research Institute for supporting innovative research in pulmonary vascular disease. The authors have no funding information to disclose."